Monogram Orthopaedics (NASDAQ:MGRM – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider & Institutional Ownership
0.4% of Monogram Orthopaedics shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 28.1% of Monogram Orthopaedics shares are held by insiders. Comparatively, 22.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Monogram Orthopaedics and NeuroPace, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monogram Orthopaedics | 0 | 0 | 1 | 1 | 3.50 |
| NeuroPace | 0 | 1 | 4 | 0 | 2.80 |
Valuation and Earnings
This table compares Monogram Orthopaedics and NeuroPace”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monogram Orthopaedics | $364,999.00 | 260.08 | -$13.74 million | ($0.46) | -5.85 |
| NeuroPace | $79.91 million | 5.28 | -$32.96 million | ($0.95) | -13.57 |
Monogram Orthopaedics has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Monogram Orthopaedics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Monogram Orthopaedics and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monogram Orthopaedics | N/A | -130.90% | -106.38% |
| NeuroPace | -36.74% | -205.41% | -28.29% |
Volatility and Risk
Monogram Orthopaedics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Summary
Monogram Orthopaedics beats NeuroPace on 10 of the 15 factors compared between the two stocks.
About Monogram Orthopaedics
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for Monogram Orthopaedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monogram Orthopaedics and related companies with MarketBeat.com's FREE daily email newsletter.
